Petros Pharmaceuticals Reports $2.25 Million Net Income for Nine Months Ended September 30, 2025

Petros Pharmaceuticals, Inc. reported a net income of $2.25 million for the nine months ended September 30, 2025, a significant turnaround from a net loss of $5.05 million during the same period in 2024. This improvement was primarily driven by a gain of $6.97 million from the assignment of subsidiaries and a settlement with Vivus, which offset losses from continuing operations. The company’s total operating expenses for the nine months increased slightly to $4.25 million from $4.05 million in the prior year, reflecting higher professional service fees. The loss from continuing operations was $4.25 million, compared to a loss of $4.05 million in the previous year.

In terms of financial position, Petros reported total assets of $6.13 million as of September 30, 2025, down from $10.64 million at the end of 2024. The decrease in assets was accompanied by a significant reduction in total liabilities, which fell to $2.77 million from $18.10 million. The company’s cash and cash equivalents increased to $6.07 million from $1.72 million, indicating improved liquidity. However, the accumulated deficit remains substantial at approximately $111 million, raising concerns about the company's long-term viability.

Strategically, Petros has undergone significant changes, including the discontinuation of its Stendra® product line and the assignment of its subsidiaries to a third party for liquidation. This shift marks a departure from its previous focus on prescription medications and medical devices, as the company aims to pivot towards the self-care market with a new integrated technology solutions platform. The platform is intended to facilitate the transition of prescription medications to over-the-counter status, aligning with recent FDA regulations.

Operationally, the company has seen a notable reduction in its workforce and customer engagement metrics due to the discontinuation of its previous product lines. The total employee headcount has not been disclosed, but the company has indicated a strategic focus on developing its new platform. Petros is also exploring additional financing options to support its operations and future growth, as it does not currently have sufficient liquidity to fund its operations for the next 12 months.

Looking ahead, Petros Pharmaceuticals acknowledges substantial doubt about its ability to continue as a going concern without raising additional capital. The company is actively evaluating various financing strategies, including public and private equity offerings, to secure the necessary funds for its operations and development initiatives. The management's outlook emphasizes the need for successful execution of its new business strategy to achieve sustainable growth and profitability.